Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types.
OBJECTIVE
To review and summarize evidence from clinical, translational and epidemiologic studies which have examined the clinically relevant aspects of HPV type prevalence and cervical dysplasia in HIV-infected women.


METHODS
Relevant studies were identified through a MEDLINE search. References of identified reports were also used to identify additional published articles for review.


RESULTS
HIV-infected women in different geographic regions (such as Zambia, Brazil, Rochester NY) appear to be infected with less prevalent types of HR-HPV as compared to the general population who, across all continents, are more commonly infected with types 16 and 18. Secondly, integration of HPV DNA into the host genome is no longer thought to be a necessary cause of malignant transformation of cervical cells. However, rate of integration appears to differ by the type of HPV. In fact, the types of HPV which appear to be more common in cervical dysplasia of HIV-infected women are the same types which are more likely to require integration for malignant transformation. Finally, HPV types found in HIV-infected women are relatively common and likely to persist. The most common among these types belong to the alpha-9 and -7 species which are the most carcinogenic species.


CONCLUSIONS
Given that current vaccines target HR-HPV-16/18, the findings from the above mentioned studies may have important implications for the design of HPV vaccines that target the types of HPV associated with disease risk in HIV-infected women. HPV typing and assessment of the physical state (whether it is integrated or episomal) appear to be two valuable parameters for the prognostic evaluation of dysplastic lesions of the uterine cervix. This, however, has not yet been assessed in HIV-infected women. Recent data about the immune response in HPV/HIV co-infection may lead to understanding potential mechanisms for less virulent HPV causing malignant transformation in HIV-infected women.
McKenzie
Nathalie Dauphin
ND
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Miami, Miller School of Medicine, Miami, FL 33129, USA. dmckenzie2@med.miami.edu
Kobetz
Erin N
EN
Hnatyszyn
James
J
Twiggs
Leo B
LB
Lucci
Joseph A
JA
D005260:Female; D005838:Genotype; D006678:HIV / Q000302:isolation & purification*; D015658:HIV Infections / Q000453:epidemiology / Q000821:virology*; D052162:Human papillomavirus 16 / Q000235:genetics / Q000302:isolation & purification*; D052161:Human papillomavirus 18 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000821:virology*; D002583:Uterine Cervical Neoplasms / Q000821:virology